C 005
Alternative Names: C-005Latest Information Update: 28 Sep 2023
At a glance
- Originator Wuxi Shuangliang Biotechnology
- Class Antineoplastics
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-small cell lung cancer
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer in China
- 03 Aug 2020 PharmAbcine enters into research collaboration agreement with Wuxi Shuangliang Biotechnology to evaluate a combination therapy of C 005 and olinvacimab in Non-small cell lung cancer
- 03 Aug 2020 Phase-I clinical trials in Non-small cell lung cancer in China (unspecified route)